Article
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Oct 2010
Johnson Faye M, Bekele B Nebiyou, Feng Lei, Wistuba Ignacio, Tang Xi Ming, Tran Hai T, Erasmus Jeremy J, Hwang Li-Ling, Takebe Naoko, Blumenschein George R, Lippman Scott M, Stewart David J
Abstract excerpt
PURPOSE: Src family kinases (SFKs) promote cancer progression and are commonly expressed in non-small-cell lung cancer (NSCLC), but the clinical effects of SFK inhibition in NSCLC are unknown. We conducted a phase II trial of the SFK inhibitor dasatinib for advanced NSCLC. We tested the hypotheses that the activation of epidermal growth factor receptor (EGFR) or SFK or modulation of serum cytokines may predict a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.